Cancer Treatment Reviews
Volume 37, Issue 3 , Pages 185-201 , May 2011

Systematic review and meta-analysis of radiotherapy in various head and neck cancers: Comparing photons, carbon-ions and protons

  • Bram L.T. Ramaekers

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, P.O. Box 1588, 6201 BN Maastricht, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 (0) 88 44 55 798; fax: +31 (0) 88 44 55 667.
    • ,
  • Madelon Pijls-Johannesma

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, P.O. Box 1588, 6201 BN Maastricht, The Netherlands
    • Tel.: +31 (0) 88 44 55 666; fax: +31 (0) 88 44 55 667.
    • ,
  • Manuela A. Joore

      Affiliations

    • Department of Health Organization, Policy and Economics (HOPE), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
    • Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
    • Tel.: +31 (0) 43 388 2907; fax: +31 (0) 43 367 0960.
    • Tel.: +31 (0) 43 387 5559; fax: +31 (0) 43 387 4419.
    • ,
  • Piet van den Ende

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, P.O. Box 1588, 6201 BN Maastricht, The Netherlands
    • Tel.: +31 (0) 88 44 55 666; fax: +31 (0) 88 44 55 667.
    • ,
  • Johannes A. Langendijk

      Affiliations

    • Department of Radiation Oncology, University Medical Center Groningen/University of Groningen, P.O. Box 30001, 9700 RB Groningen, The Netherlands
    • Tel.: +31 (0) 50 361 5532; fax: +31 (0) 50 361 3672.
    • ,
  • Philippe Lambin

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, P.O. Box 1588, 6201 BN Maastricht, The Netherlands
    • Tel.: +31 (0) 88 44 55 666; fax: +31 (0) 88 44 55 667.
    • ,
  • Alfons G.H. Kessels

      Affiliations

    • Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
    • Tel.: +31 (0) 43 387 5559; fax: +31 (0) 43 387 4419.
    • These authors contributed equally to this work.
    • ,
  • Janneke P.C. Grutters

      Affiliations

    • Department of Health Organization, Policy and Economics (HOPE), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
    • Tel.: +31 (0) 43 388 2907; fax: +31 (0) 43 367 0960.
    • These authors contributed equally to this work.

Received 21 June 2010 ,Revised 4 August 2010 ,Accepted 8 August 2010.

References 

  1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592
  2. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:47–56
  3. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–854
  4. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol. 2009;92:4–14
  5. Duke RL, Campbell BH, Indresano AT, et al. Dental status and quality of life in long-term head and neck cancer survivors. Laryngoscope. 2005;115:678–683
  6. Hammerlid E, Silander E, Hornestam L, Sullivan M. Health-related quality of life three years after diagnosis of head and neck cancer – a longitudinal study. Head Neck. 2001;23:113–125
  7. Jensen AB, Hansen O, Jorgensen K, Bastholt L. Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer. Acta Oncol. 1994;33:487–491
  8. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26:3770–3776
  9. List MA, Bilir SP. Functional outcomes in head and neck cancer. Semin Radiat Oncol. 2004;14:178–189
  10. Durante M, Loeffler JS. Charged particles in radiation oncology. Nat Rev Clin Oncol. 2010;7:37–43
  11. Glimelius B, Ask A, Bjelkengren G, et al. Number of patients potentially eligible for proton therapy. Acta Oncol. 2005;44:836–849
  12. Palm A, Johansson KA. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors. Acta Oncol. 2007;46:462–473
  13. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol. 2007;25:965–970
  14. Jereczek-Fossa BA, Krengli M, Orecchia R. Particle beam radiotherapy for head and neck tumors: radiobiological basis and clinical experience. Head Neck. 2006;28:750–760
  15. Lodge M, Pijls-Johannesma M, Stirk L, Munro AJ, De Ruysscher D, Jefferson T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol. 2007;83:110–122
  16. Chan AW, Liebsch NJ. Proton radiation therapy for head and neck cancer. J Surg Oncol. 2008;97:697–700
  17. Ask A, Bjork-Eriksson T, Zackrisson B, Blomquist E, Glimelius B. The potential of proton beam radiation therapy in head and neck cancer. Acta Oncol. 2005;44:876–880
  18. Schulz-Ertner D, Jakel O, Schlegel W. Radiation therapy with charged particles. Semin Radiat Oncol. 2006;16:249–259
  19. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25:953–964
  20. Brada M, Pijls-Johannesma M, De Ruysscher D. Current clinical evidence for proton therapy. Cancer J. 2009;15:319–324
  21. Pijls-Johannesma M, Pommier P, Lievens Y. Cost-effectiveness of particle therapy: current evidence and future needs. Radiother Oncol. 2008;89:127–134
  22. Glimelius B, Isacsson U, Blomquist E, Grusell E, Jung B, Montelius A. Potential gains using high-energy protons for therapy of malignant tumours. Acta Oncol. 1999;38:137–145
  23. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123:A12–A13
  24. Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index: a review. Int J Radiat Oncol Biol Phys. 2006;64:333–342
  25. Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys. 2010;76:S28–S35
  26. Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys. 2010;76:S58–S63
  27. Caudell JJ, Burnett OL, Schaner PE, Bonner JA, Duan J. Comparison of methods to reduce dose to swallowing-related structures in head and neck cancer. Int J Radiat Oncol Biol Phys. 2010;77:462–467
  28. Rancati T, Schwarz M, Allen AM, et al. Radiation dose-volume effects in the larynx and pharynx. Int J Radiat Oncol Biol Phys. 2010;76:S64–S69
  29. Moore DS, McCabe GP, Craig BA. Introduction to the practice of statistics. 6th ed.. W.H. Freeman Company; 2009;
  30. Cantor AB. Projecting the standard error of the Kaplan–Meier estimator. Stat Med. 2001;20:2091–2097
  31. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II analysis and examples. Br Journal of Cancer. 1973;35:1–39
  32. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?. Stat Med. 2002;21:1559–1573
  33. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012
  34. Mizoe JE, Hasegawa A, Bessho H, Jingu K, Kakimoto Y. Head and neck tumors. In: Proceedings of NIRS-ETOILE: joint symposium 2009 on carbon ion radiotherapy. Lyon; 2009.
  35. Mizoe JE, Tsujii H, Kamada T, et al. Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;60:358–364
  36. Tokuuye K, Akine Y, Kagei K, et al. Proton therapy for head and neck malignancies at Tsukuba. Strahlenther Onkol. 2004;180:96–101
  37. Milano MT, Vokes EE, Kao J, et al. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006;28:1141–1151
  38. Monroe AT, Young JA, Huff JD, Ernster JA, White GA, Peddada AV. Accelerated fractionation head and neck intensity-modulated radiation therapy and concurrent chemotherapy in the community setting: safety and efficacy considerations. Head Neck. 2009;31:1144–1151
  39. Rades D, Fehlauer F, Wroblesky J, Albers D, Schild SE, Schmidt R. Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. Oral Oncol. 2007;43:535–543
  40. Studer G, Furrer K, Davis BJ, et al. Postoperative IMRT in head and neck cancer. Radiat Oncol. 2006;1:40
  41. Seung S, Bae J, Solhjem M, et al. Intensity-modulated radiotherapy for head-and-neck cancer in the community setting. Int J Radiat Oncol Biol Phys. 2008;72:1075–1081
  42. Lauve A, Morris M, Schmidt-Ullrich R, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II – clinical results. Int J Radiat Oncol Biol Phys. 2004;60:374–387
  43. Nangia S, Chufal KS, Tyagi A, Bhatnagar A, Mishra M, Ghosh D. Selective nodal irradiation for head and neck cancer using intensity-modulated radiotherapy: application of RTOG consensus guidelines in routine clinical practice. Int J Radiat Oncol Biol Phys; 2009.
  44. Saba NF, Edelman S, Tighiouart M, et al. Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: a retrospective single-institution analysis. Head Neck. 2009;31:1447–1455
  45. Chan AW, Liebsch LJ, Deschler DG, et al. Proton radiotherapy for T4 nasopharyngeal carcinoma. J Clin Oncol (Meeting Abstracts). 2004;22:5574
  46. Chong Z. Improved local control with intensity modulated radiation therapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2004;60:S317
  47. Fang FM, Chien CY, Tsai WL, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy – a longitudinal study. Int J Radiat Oncol Biol Phys. 2008;72:356–364
  48. Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2004;60:1440–1450
  49. Kim K, Wu HG, Kim HJ, et al. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Head Neck. 2009;31:1121–1128
  50. Koom WS, Kim TH, Shin KH, et al. SMART (simultaneous modulated accelerated radiotherapy) for locally advanced nasopharyngeal carcinomas. Head Neck. 2008;30:159–169
  51. Kwong DL, Pow EH, Sham JS, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer. 2004;101:1584–1593
  52. Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27:3684–3690
  53. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12–22
  54. Lin S, Pan J, Han L, Zhang X, Liao X, Lu JJ. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys. 2009;75:1071–1078
  55. Nishimura Y, Shibata T, Nakamatsu K, et al. A two-step intensity-modulated radiation therapy method for nasopharyngeal cancer: the Kinki University experience. Jpn J Clin Oncol. 2009;40:130–138
  56. Tham IW, Hee SW, Yeo RM, et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy – The National Cancer Centre Singapore experience. Int J Radiat Oncol Biol Phys. 2009;75:1481–1486
  57. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys. 2006;64:57–62
  58. Wong FC, Ng AW, Lee VH, et al. Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009;76:138–145
  59. Zheng J, Wang G, Yang GY, et al. Induction chemotherapy with nedaplatin with 5-FU followed by intensity-modulated radiotherapy concurrent with chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Jpn J Clin Oncol 2010 [Epub ahead of print].
  60. Slater JD, Yonemoto LT, Mantik DW, et al. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. Int J Radiat Oncol Biol Phys. 2005;62:494–500
  61. Chao KS, Ozyigit G, Blanco AI, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys. 2004;59:43–50
  62. Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 2009.
  63. Garden AS, Morrison WH, Wong PF, et al. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;67:438–444
  64. Huang K, Lee N, Xia P, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal carcinoma: a single institutional experience. Int J Radiat Oncol Biol Phys. 2003;57:S302
  65. Lawson JD, Otto K, Chen A, Shin DM, Davis L, Johnstone PA. Concurrent platinum-based chemotherapy and simultaneous modulated accelerated radiation therapy for locally advanced squamous cell carcinoma of the tongue base. Head Neck. 2008;30:327–335
  66. Lee NY, de Arruda FF, Puri DR, et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:966–974
  67. Rusthoven KE, Raben D, Ballonoff A, Kane M, Song JI, Chen C. Effect of radiation techniques in treatment of oropharynx cancer. Laryngoscope. 2008;118:635–639
  68. Schoenfeld GO, Amdur RJ, Morris CG, Li JG, Hinerman RW, Mendenhall WM. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;71:377–385
  69. Yao M, Nguyen T, Buatti JM, et al. Changing failure patterns in oropharyngeal squamous cell carcinoma treated with intensity modulated radiotherapy and implications for future research. Am J Clin Oncol. 2006;29:606–612
  70. Daly ME, Le QT, Maxim PG, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010;76:1339–1346
  71. Nishimura H, Ogino T, Kawashima M, et al. Proton-beam therapy for olfactory neuroblastoma. Int J Radiat Oncol Biol Phys. 2007;68:758–762
  72. Resto VA, Chan AW, Deschler DG, Lin DT. Extent of surgery in the management of locally advanced sinonasal malignancies. Head Neck. 2008;30:222–229
  73. Daly ME, Chen AM, Bucci MK, et al. Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2007;67:151–157
  74. Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys. 2009;73:424–432
  75. Weber DC, Chan AW, Lessell S, et al. Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons. Radiother Oncol. 2006;81:243–249
  76. Mizoe JE, Hasegawa A, Bessho H, Jingu K, Kakimoto Y. Phase II clinical trial for mucosal malignant melanoma of the head and neck combined with chemotherapy (protocol 0007). In: Proceedings of NIRS-ETOILE: joint symposium 2009 on carbon ion radiotherapy. Lyon; 2009.
  77. Andersen LJ, Berthelsen A, Hansen HS. Malignant melanoma of the upper respiratory tract and the oral cavity. J Otolaryngol. 1992;21:180–185
  78. Bridger AG, Smee D, Baldwin MA, Kwok B, Bridger GP. Experience with mucosal melanoma of the nose and paranasal sinuses. ANZ J Surg. 2005;75:192–197
  79. Gilligan D, Slevin NJ. Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses. Br J Radiol. 1991;64:1147–1150
  80. Guzzo M, Grandi C, Licitra L, Podrecca S, Cascinelli N, Molinari R. Mucosal malignant melanoma of head and neck: forty-eight cases treated at Istituto Nazionale Tumori of Milan. Eur J Surg Oncol. 1993;19:316–319
  81. Huang SF, Liao CT, Kan CR, Chen IH. Primary mucosal melanoma of the nasal cavity and paranasal sinuses: 12 years of experience. J Otolaryngol. 2007;36:124–129
  82. Kingdom TT, Kaplan MJ. Mucosal melanoma of the nasal cavity and paranasal sinuses. Head Neck. 1995;17:184–189
  83. Krengli M, Masini L, Kaanders JH, et al. Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2006;65:751–759
  84. Loree TR, Mullins AP, Spellman J, North JH, Hicks WL. Head and neck mucosal melanoma: a 32-year review. Ear Nose Throat J. 1999;78:372–375
  85. Lund VJ, Howard DJ, Harding L, Wei WI. Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope. 1999;109:208–211
  86. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer. 1997;80:1373–1386
  87. Meleti M, Leemans CR, de Bree R, Vescovi P, Sesenna E, van der Waal I. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck. 2008;30:1543–1551
  88. Nakashima JP, Viegas CM, Fassizoli AL, et al. Postoperative adjuvant radiation therapy in the treatment of primary head and neck mucosal melanomas. ORL J Otorhinolaryngol Relat Spec. 2008;70:344–351
  89. Owens JM, Roberts DB, Myers JN. The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg. 2003;129:864–868
  90. Patel SG, Prasad ML, Escrig M, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck. 2002;24:247–257
  91. Shibuya H, Takeda M, Matsumoto S, Hoshina M, Suzuki S, Takagi M. The efficacy of radiation therapy for a malignant melanoma in the mucosa of the upper jaw: an analytic study. Int J Radiat Oncol Biol Phys. 1993;25:35–39
  92. Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005;103:313–319
  93. Wagner M, Morris CG, Werning JW, Mendenhall WM. Mucosal melanoma of the head and neck. Am J Clin Oncol. 2008;31:43–48
  94. Yii NW, Eisen T, Nicolson M, et al. Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century. Clin Oncol (R Coll Radiol). 2003;15:199–204
  95. Yanagi T, Mizoe JE, Hasegawa A, et al. Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys. 2009;74:15–20
  96. Schulz-Ertner D, Nikoghosyan A, Didinger B, et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer. 2005;104:338–344
  97. Munter M, Umathum V, Nikoghosyan A, et al. Combination of intensity modulated radiation therapy (IMRT) and a carbon ion boost for subtotal resected or inoperable adenoid cystic carcinomas (ACC’s) of the head and neck region. Heidelberg; 2009 [PTCOG 48].
  98. Pommier P, Liebsch NJ, Deschler DG, et al. Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132:1242–1249
  99. Agarwal JP, Jain S, Gupta T, et al. Intraoral adenoid cystic carcinoma: prognostic factors and outcome. Oral Oncol. 2008;44:986–993
  100. Avery CM, Moody AB, McKinna FE, Taylor J, Henk JM, Langdon JD. Combined treatment of adenoid cystic carcinoma of the salivary glands. Int J Oral Maxillofac Surg. 2000;29:277–279
  101. Bhattacharyya N, Fried MP. Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol. 2005;26:39–44
  102. Da Cruz Perez DE, Pires FR, Lopes MA, de Almeida OP, Kowalski LP. Adenoid cystic carcinoma and mucoepidermoid carcinoma of the maxillary sinus: report of a 44-year experience of 25 cases from a single institution. J Oral Maxillofac Surg. 2006;64:1592–1597
  103. Garden AS, Weber RS, Morrison WH, Ang KK, Peters LJ. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys. 1995;32:619–626
  104. Gomez DR, Hoppe BS, Wolden SL, et al. Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck: a recent experience. Int J Radiat Oncol Biol Phys. 2008;70:1365–1372
  105. Gurney TA, Eisele DW, Weinberg V, Shin E, Lee N. Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation. Laryngoscope. 2005;115:1278–1282
  106. Harbo G, Bundgaard T, Pedersen D, Sogaard H, Overgaard J. Prognostic indicators for malignant tumours of the parotid gland. Clin Otolaryngol Allied Sci. 2002;27:512–516
  107. Hosokawa Y, Ohmori K, Kaneko M, et al. Analysis of adenoid cystic carcinoma treated by radiotherapy. Oral Surg Oral Med Oral Pathol. 1992;74:251–255
  108. Hsu HC, Huang EY, Wang CJ. Postoperative adjuvant radiotherapy for adenoid cystic carcinoma of the head and neck: treatment results and prognostic factors. Chang Gung Med J. 2003;26:646–653
  109. Huber PE, Debus J, Latz D, et al. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam?. Radiother Oncol. 2001;59:161–167
  110. Iseli TA, Karnell LH, Graham SM, et al. Role of radiotherapy in adenoid cystic carcinoma of the head and neck. J Laryngol Otol. 2009;1–8
  111. Khan AJ, DiGiovanna MP, Ross DA, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 2001;96:149–158
  112. Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE. Adenoid cystic carcinoma of the head and neck – a 20 years experience. Int J Oral Maxillofac Surg. 2004;33:25–31
  113. Leonetti JP, Marzo SJ, Agarwal N. Adenoid cystic carcinoma of the parotid gland with temporal bone invasion. Otol Neurotol. 2008;29:545–548
  114. Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Hinerman RW, Villaret DB. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck. 2004;26:154–162
  115. Rapidis AD, Givalos N, Gakiopoulou H, et al. Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol. 2005;41:328–335
  116. Rhee CS, Won TB, Lee CH, et al. Adenoid cystic carcinoma of the sinonasal tract: treatment results. Laryngoscope. 2006;116:982–986
  117. Silverman DA, Carlson TP, Khuntia D, Bergstrom RT, Saxton J, Esclamado RM. Role for postoperative radiation therapy in adenoid cystic carcinoma of the head and neck. Laryngoscope. 2004;114:1194–1199
  118. Spiro RH, Huvos AG. Stage means more than grade in adenoid cystic carcinoma. Am J Surg. 1992;164:623–628
  119. Takagi D, Fukuda S, Furuta Y, et al. Clinical study of adenoid cystic carcinoma of the head and neck. Auris Nasus Larynx. 2001;28(Suppl.):S99–S102
  120. Therkildsen MH, Christensen M, Andersen LJ, Schiodt T, Hansen HS. Salivary gland carcinomas–prognostic factors. Acta Oncol. 1998;37:701–713
  121. Amirul Islam M, Yanagi T, Mizoe JE, Mizuno H, Tsujii H. Comparative study of dose distribution between carbon ion radiotherapy and photon radiotherapy for head and neck tumor. Radiat Med. 2008;26:415–421
  122. Cozzi L, Fogliata A, Lomax A, Bolsi A. A treatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours. Radiother Oncol. 2001;61:287–297
  123. Johansson J, Blomquist E, Montelius A, Isacsson U, Glimelius B. Potential outcomes of modalities and techniques in radiotherapy for patients with hypopharyngeal carcinoma. Radiother Oncol. 2004;72:129–138
  124. Mock U, Georg D, Bogner J, Auberger T, Potter R. Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2004;58:147–154
  125. Steneker M, Lomax A, Schneider U. Intensity modulated photon and proton therapy for the treatment of head and neck tumors. Radiother Oncol. 2006;80:263–267
  126. Taheri-Kadkhoda Z, Bjork-Eriksson T, Nill S, et al. Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protons. Radiat Oncol. 2008;3:4
  127. Van de Water T, Lomax A, Bijl H, et al. Comparative treatment planning study between scanned intensity modulated proton therapy and photon therapy in complex oropharyngeal carcinoma. ESTRO. Göteborg; 2008.
  128. Widesott L, Pierelli A, Fiorino C, et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int J Radiat Oncol Biol Phys. 2008;72:589–596
  129. Krengli M, Jereczek-Fossa BA, Kaanders JH, Masini L, Beldi D, Orecchia R. What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck?. Crit Rev Oncol Hematol. 2008;65:121–128
  130. Overgaard J. The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys. 1986;12:867–872
  131. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999;28:1–9
  132. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2008.
  133. PTCOG. Statistics of patients treated in hadron therapy centers worldwide; 2009. Available from: http://ptcog.web.psi.ch/patient_statistics.html [accessed 2009].
  134. Sayed SI, Elmiyeh B, Rhys-Evans P, et al. Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions. Cancer Treat Rev 2009.
  135. Goitein M. Trials and tribulations in charged particle radiotherapy. Radiother Oncol. 2010;95:23–31
  136. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;45:577–587
  137. Roesink JM, Moerland MA, Hoekstra A, Van Rijk PP, Terhaard CH. Scintigraphic assessment of early and late parotid gland function after radiotherapy for head-and-neck cancer: a prospective study of dose-volume response relationships. Int J Radiat Oncol Biol Phys. 2004;58:1451–1460
  138. Semenenko VA, Li XA. Lyman–Kutcher–Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data. Phys Med Biol. 2008;53:737–755
  139. Schilstra C, Meertens H. Calculation of the uncertainty in complication probability for various dose-response models, applied to the parotid gland. Int J Radiat Oncol Biol Phys. 2001;50:147–158

PII: S0305-7372(10)00139-8

doi: 10.1016/j.ctrv.2010.08.004

Cancer Treatment Reviews
Volume 37, Issue 3 , Pages 185-201 , May 2011

Article Tools

* Image Usage & Resolution